BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.71 +2.35%

+$0.47 today

Market cap
$177.33M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.78M

Average 0.46M

BIOA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

BioAge Labs, Inc.NASDAQ: BIOA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $2.71M rose 86.7% year over year, behind the +606.6% change in trailing-twelve-month gross profit. Sequentially, it fell 12.0% from the prior quarter.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +86.7% toward the trailing-twelve-month pace of +606.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.71M-12.0% QoQ
Last fiscal yearDec 2025
$9M— YoY
LTMMar 2026
$10.25M+606.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86.7%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
9M USD
Year-over-year change
—

Gross Profit vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +606.6% is the highest of 8, against a peer median of -2.3%.
  • Gross profit amounts to 99.4% of revenue for BIOA, versus a peer median of 32.2%.
BIOA Competitors
Gross Profit for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$176.08M CAD-6.1%+4.2%56.6%
CGCCanopy Growth CorporationLTM Mar 2026CA$77.66M CAD-2.3%—24.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$42.13M USD—+1.0%31.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$13.93M USD+73.5%-8.4%33.3%
BIOABioAge Labs, Inc.LTM Mar 2026$10.25M USD+606.6%—99.4%
EDITEditas Medicine, Inc.LTM Mar 2026$2.25M USD+105.3%+44.7%5.8%
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
HUMAHumacyte, Inc.LTM Mar 2026-$15.09M USD-917.5%—748.5%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$40.76M USD-72.9%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$77.25M USD+23.8%——
Peer median (excluding BIOA) —-2.3%+2.6%32.2%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.